Luvadaxistat also affected ASSR
SECONDARY
ASSR gamma band power was another NMDA-related secondary endpoint in the study. The LS mean change ± SEM from baseline in ASSR gamma band power at day 8 was 2.135 ± 8.83 for subjects treated with luvadaxistat 50 mg QD compared with −16.282 ± 9.31 for those treated with placebo and was 9.411 ± 20.4 for subjects treated with luvadaxistat 500 mg QD compared with 9.203 ± 20.9 for those treated with placebo (Figs. 